ATLANTA–(BUSINESS WIRE)–CareSource, a nationally recognized nonprofit health plan serving more than 440,000 Georgians, announced an enhanced benefits package for its Dual Eligible Special Needs Plan (DSNP). The plan is designed to help members lead h…
Author: Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
CUMBERLAND, R.I.–(BUSINESS WIRE)–Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription Drug User Fee Act …
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024. “Avenova sales through the online channel for the quarter increased 14% over the …
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a leading provide…
Warby Parker Announces Third Quarter 2024 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2024. “Warby Parker…
Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
GENEVA–(BUSINESS WIRE)–Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC (“PRN”…
Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists, from…
National Vision Holdings, Inc. Reports Third Quarter 2024 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the third quarter ended September 28, 2024. “We are encouraged by the progress we are making agains…
National Vision Completes Comprehensive Review of Store Fleet
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced the results of its comprehensive store fleet review. In August 2024, the Company announced it had identified an initial list…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announce…
Horus Pharma Pushes Ahead With Its European Expansion
NICE, France & BUCHAREST, Romania–(BUSINESS WIRE)–Horus Pharma, an independent French company that is the leading player in ophthalmology, is announcing its first investment in a company outside France with the purchase of a significant participation…
Georgia State Parks Introduce Free Colorblind-Adapting Glasses at Cloudland Canyon, Sweetwater Creek and Skidaway Island
ATLANTA–(BUSINESS WIRE)– #enchroma–Georgia’s State Parks continue to enhance accessibility in new and innovative ways, with the latest addition being EnChroma colorblind glasses at three of its most popular destinations: Cloudland Canyon, Sweetwater…
poLight ASA Delivers the ‘Human Eye Experience’ at CES 2025
HORTEN, Norway–(BUSINESS WIRE)– #AR–poLight ASA (OSE: PLT) will demo its tunable optics technology delivering ‘the human eye experience’ at CES®, Jan. 7-10, 2025 in Las Vegas, Nevada.
LumiThera obtient l'agrément de la FDA pour son traitement Valeda, qui améliore la vision des patients atteints de DMLA sèche
SEATTLE–(BUSINESS WIRE)–LumiThera Inc. est une société spécialisée dans les dispositifs médicaux qui propose un traitement par photobiomodulation (PBM) des lésions et maladies oculaires ; elle a annoncé aujourd’hui que la FDA (Food & Drug Adminis…
Riassunto: LumiThera ottiene l’autorizzazione della FDA al trattamento con Valeda per pazienti affetti dalla forma atrofica della AMD per migliorare la funzionalità visiva
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., produttore di dispositivi medici che offre un trattamento di fotobiomodulazione (PBM) per patologie e lesioni oculari, oggi ha annunciato che l’agenzia federale statunitense per gli alimenti e i farmaci (FDA) h…
Resumen: La empresa LumiThera obtiene la autorización de la FDA para el tratamiento Valeda para mejorar la visión en pacientes con DMAE seca
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., una empresa de dispositivos médicos que ofrece tratamiento de fotobiomodulación (PBM) para enfermedades y daños oculares, anunció hoy que la Administración de Alimentos y Medicamentos de EE.UU. (FDA) ha autoriz…
Samenvatting: LumiThera verkrijgt FDA-autorisatie voor Valeda-behandeling voor droge AMD-patiënten om het zicht te verbeteren
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., een medisch apparaatbedrijf dat fotobiomodulatie (PBM)-behandelingen aanbiedt voor oculaire schade en ziekte, heeft vandaag aangekondigd dat de Amerikaanse Food & Drug Administration (FDA) de marketing van …
LumiThera erhält FDA-Zulassung für Valeda-Behandlung zur Verbesserung der Sehkraft bei trockener AMD
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., ein Unternehmen für medizinische Geräte, das photobiomodulatorische (PBM) Behandlungen für Augenschäden und -erkrankungen anbietet, gab heute bekannt, dass die US-amerikanische Food & Drug Administration (F…